

PE Titan Holding II Limited

Annual Report and Financial Statements

For the year ended 31 December 2022

UK Registration Number: 11243295

THURSDAY



ACGG7K8Y

A17

16/11/2023

#113

COMPANIES HOUSE

Directors and Advisers for the Year Ended 31 December 2022	3
Directors' Report for the Year Ended 31 December 2022	4
Statements of Financial Position	6
Statements of Total Comprehensive Income	7
Statements of Changes in Equity	8
Notes to the Annual Financial Statements	9
1. Nature of operations	9
2. Basis of preparation	9
3. Significant accounting policies	9
4. Cash and cash equivalents	14
5. Interest receivable – related party	14
6. Loans receivable – related party	14
7. Investment in subsidiary	15
8. Income taxes	15
9. Fair value measurements	16
10. Ordinary and preference shares	16
11. Interest income	16
12. Risk management	16
13. Indemnifications	17
14. Related party disclosures	17
15. Ultimate controlling company and parent company of larger group	24
16. Directors' remuneration	24
17. Subsequent events	24

Directors and Advisers for the Year Ended 31 December 2022

Directors

Eva Monica Kalawski
Ian Michael Stuart Downie
Mary Ann Sigler

Company Secretary

Eva Monica Kalawski

Solicitors

Baker & McKenzie
100 New Bridge Street
London EC4V 6JA

Bankers

Comerica Bank
1021 Glendon Avenue
Los Angeles, CA 90024-4595

Registered office

100 New Bridge Street
London EC4V 6JA

Registration number

11243295

Directors' Report for the Year Ended 31 December 2022

The directors present their report and the financial statements of PE Titan Holding II Limited (the "Company") for the year ended 31 December 2022.

Principal activities

The principal activities during the year were those of a holding company.

Review of the business

The Company's primary purpose is that of a holding company to make investments in and loans to PE Titan III Limited, a private company limited by shares incorporated in the United Kingdom ("PE Titan III").

The net income for the year ended 31 December 2022 amounted to \$37.8 million. As at 31 December 2022, the total assets were \$909.4 million and the total liabilities were \$34.9 million for total equity of \$874.6 million.

Directors

The directors of the Company who were in office during the year and up to the date of signing the financial statements were:

Eva Monica Kalawski
Ian Michael Stuart Downie
Mary Ann Sigler

The Company maintained liability insurance, which includes indemnity for its directors and officers, which is a qualifying third-party indemnity provision for the purposes of the Companies Act 2006 and was in force during the entire financial year and as of the date of approval of the financial statements.

Going concern and liquidity

The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. The Company plans to offset the loan receivable from shareholders with the dividends payable. Thus, they continue to adopt the going concern basis in preparing the financial statements.

Statement of directors' responsibilities

The directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable laws and regulations.

The Companies Act 2006 requires the directors to prepare financial statements for each financial year. Under that law, the directors have prepared the financial statements in accordance with United Kingdom General Accepted Accounting Practice and applicable law. Under Company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and accounting estimates that are reasonable and prudent;
- State whether applicable United Kingdom General Accepted Accounting Practice has been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.


The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small companies exemptions

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

On behalf of the Board

WRB



Mary Ann Sigler
Director
Date:

Statements of Financial Position

In millions of U.S. dollars


Assets	Note	As at December 31,	
		2022	2021
Non-current assets			
Loans receivable - related party	6	\$ 486.1	\$ 486.1
Investment in subsidiary	7	\$ 272.3	\$ 272.3
Total non-current assets		\$ 758.4	\$ 758.4
Cash and cash equivalents			
Cash and cash equivalents	4	\$ 0.2	\$ 0.2
Loan receivable from shareholders	14	\$ -	\$ -
Interest receivable - related party	5	\$ 150.8	\$ 104.1
Total current assets		\$ 151.0	\$ 104.3
Total assets		\$ 909.4	\$ 862.7
Liabilities and equity			
Loans payable - related party		\$ 34.8	\$ 25.9
Dividends payable	14	\$ -	\$ -
Total current liabilities		\$ 34.8	\$ 25.9
Equity			
Ordinary shares	10	\$ 546.3	\$ 546.3
Share premium	10	\$ 179.9	\$ 179.9
Retained earnings		\$ 148.4	\$ 110.6
Total equity		\$ 874.6	\$ 836.8
Total liabilities and equity		\$ 909.4	\$ 862.7

See the accompanying notes to the financial statements.

For the years ending 31 December 2022 and 2021, PE Titan Holding II Limited (the "Company") was entitled to exemption from audit under section 479A of the Companies Act 2006 related to subsidiary companies. The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and preparation of accounts. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of Financial Reporting Standard ("FRS") 102 Section 1A - small entities.

These financial statements were approved by the Board of Directors and were signed on its behalf by:

WRB 

Mary Ann Sigler, Director
Date:

Statements of Total Comprehensive Income

In millions of U.S. dollars

	Note	For the years ended December 31,	
		2022	2021
Interest income	11	\$ 46.7	\$ 43.3
Income before income taxes		\$ 46.7	\$ 43.3
Provision for (recovery of) income taxes			
Deferred	8	\$ 8.9	\$ 8.2
Total income taxes	8	\$ 8.9	\$ 8.2
Net income		\$ 37.8	\$ 35.1
Total comprehensive income, net of tax		\$ 37.8	\$ 35.1
Attributable to:			
Equity holders of Parent		\$ 24.0	\$ 22.3
Non-controlling interests		\$ 13.8	\$ 12.8
Total comprehensive income		\$ 37.8	\$ 35.1

See the accompanying notes to the financial statements.

Statements of Changes in Equity

In millions of U.S. dollars and millions of shares

	Note	Ordinary shares		Share Premium	Retained earnings	Total equity
		Shares	Amount			
Balance as at December 31, 2020		546,297,306.2	\$ 546.3	\$ 179.9	\$ 75.5	\$ 801.7
Net income		-	-	-	\$ 35.1	\$ 35.1
Balance as at December 31, 2021		546,297,306.2	\$ 546.3	\$ 179.9	\$ 110.6	\$ 836.8
Net income		-	-	-	\$ 37.8	\$ 37.8
Balance as at December 31, 2022		546,297,306.2	\$ 546.3	\$ 179.9	\$ 148.4	\$ 874.6

See the accompanying notes to the financial statements.

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

1. Nature of operations

PE Titan Holding II Limited (the "Company") is a private company limited by shares. The Company's primary purpose is that of a holding company to make investments in and loans to its subsidiary, PE Titan Holding III Limited, a private company limited by shares incorporated in the United Kingdom ("PE Titan III").

The Company is incorporated under the laws of England and Wales. Its head office is located at 100 New Bridge Street, London EC4V 6JA.

2. Basis of preparation

The financial statements have been prepared in accordance with United Kingdom General Accepted Accounting Practice FRS 101, *Reduced Disclosure Framework* ("FRS 101") of the United Kingdom. The Company has taken advantage of the exemption under FRS 101 not to present the cash flow statements as required under International Accounting Standard ("IAS") 7 *Statement of Cash Flows*.

Management of the Company prepared the financial statements for the years ended 31 December 2022 and 2021. The financial statements of the Company are drawn up in millions of United States ("U.S.") dollars.

The Company has taken advantage of the exemption under section 401 of the Companies Act 2006 not to prepare group accounts as they are prepared by its immediate parent undertaking PE Titan Holding Limited ("PE Titan"), which is incorporated in the United Kingdom. Group financial statements for PE Titan are available from the address detailed in note 15.

3. Significant accounting policies

(A) Investments

The Company accounts for its investments in subsidiaries at cost less impairments.

(B) Use of estimates

The preparation of financial statements under International Financial Reporting Standards ("IFRS") requires management to make estimates and assumptions that affect the amounts reported in the financial statements. The most significant assumptions are estimates in determining the fair value of its loan receivable from PE Titan III. Management annually reassess expected credit losses on intercompany receivables.

(C) Standards issued but not yet effective

Certain new accounting standards, amendments and interpretations have been published that are not mandatory for the 31 December 2022 reporting year. The Company has early adopted the applicable accounting standards, amendments and interpretations.

(D) Cash and cash equivalents

Cash and cash equivalents include cash on accounts and short-term investments in term deposits with maturities of three months or less from the date of acquisition and are valued at cost plus accrued interest, which approximates fair value.

Notes to the Annual Financial Statements

Year Ended 31 December 2022

In millions of U.S dollars and millions of shares

(E) Financial instruments

Measurement

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial instruments classified as amortized costs or Fair Value Through the statement of Other Comprehensive Income ("FVTOCI") are included with the carrying amount of such instruments. Transaction costs that are directly attributable to the acquisition or issue of financial instruments classified as fair value through profit or loss ("FVTPL") are recognized immediately in the profit or loss within the statement of total comprehensive income. Financial assets purchased and sold, where the contract requires the asset to be delivered within an established time frame, are recognized on a trade date basis.

Financial assets

The Company classifies its financial assets under its business model in the following measurement categories:

- Those to be measured subsequently at amortized cost; and
- Those to be measured subsequently at either FVTOCI or FVTPL.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. All the entity's financial assets and financial liabilities, except derivatives not within a hedge, are classified as principal and interest and use amortized cost.

Financial assets at amortized cost

Financial assets that meet the following conditions are measured at amortized cost less impairment losses (if any):

- The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash-flows.
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
- The financial asset was not acquired principally for the purpose of selling in the near term or for short-term profit taking (held for trading).

Financial assets at FVTPL

All other financial assets, except equity and debt instruments are remeasured at fair value and classified as FVTPL. The gains or losses, if any, arising on remeasurement of FVTPL are recognized in profit or loss within the statement of comprehensive income. The method of measurement of instruments in debt instruments will depend on the business model in which the instrument is held. For instruments in equity instruments, it will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for the equity instrument at FVTOCI.

Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest. The Company has no financial assets with embedded derivatives.

Financial liabilities

Financial liabilities are classified as FVTPL when the financial liability is either held for trading or is designated at FVTPL. Financial liabilities at FVTPL are remeasured in subsequent reporting periods at fair value. Any gains or losses arising on remeasurement of held for trading financial liabilities are recognized in profit or loss within

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

the statement of total comprehensive income. Such gains or losses recognized in profit or loss includes any interest paid on the financial liabilities.

Financial liabilities that are not held for trading and are not designated as FVTPL are measured at amortized cost. The carrying amounts of financial liabilities that are measured at amortized cost are determined based on the effective interest rate method. The effective interest rate method is a method of calculating the amortized cost of a financial liability (or financial asset) and of allocating interest expense (or income) over the expected life of the financial liability (or financial asset).

Long-term borrowings

Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest rate method. Fees paid on the establishment of loan facilities are recognized as transaction costs of the loan.

Borrowings are derecognized from the statement of financial position when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

Expected credit losses

The Company assesses, on a forward-looking basis, the expected credit losses associated with its assets carried at amortized cost and FVTOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount reported in the statement of financial position if, and only if, there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

Embedded derivatives

International Financial Reporting Standards ("IFRS") 9, *Financial Instruments*, requires that under certain conditions, an embedded derivative is separated from its host contract and accounted for as a derivative or the entire contract is to be measured at FVTPL. An embedded derivative causes some or all of the cash flows that otherwise would be required by the contract to be modified according to a special interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, a credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract. The Company did not hold any material embedded derivatives as at 31 December 2022 and 2021.

(F) Fair value measurements

The Company measures the fair value of assets and liabilities on a recurring and non-recurring basis in accordance with IFRS 13, *Fair Value Measurement* ("IFRS 13"), which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. IFRS 13 establishes a framework for measuring fair value.

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

This guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value as follows:

Level 1 Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

Level 2 Observable inputs, other than Level 1 inputs, such as quoted prices for similar assets and liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3 Inputs that are unobservable.

An asset's or a liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes observable requires judgment by the Company.

(G) Foreign currency translation

The Company's financial statements are presented in U.S. dollars, which is also the Company's functional currency.

Transactions in foreign currencies, if any, are initially recorded by the Company at their respective functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Differences arising on settlement or translation of monetary items are recognized in profit or loss with the exception of certain items that are designated as part of a hedge, which are recognized in other comprehensive income ("OCI") until settled.

(H) Preference shares

Preference shares are classified as equity. If there are sufficient distributable profits and should the Company declare a preference dividend, the preference dividend shall automatically become a debt due and immediately payable on the payment date. The Company shall redeem each preference share on the earliest of: the 20th anniversary of the issue date for the share, the Company giving notice to the preference shareholder, or the preference shareholder giving notice to the Company. On the redemption date, the Company shall pay the preference shareholder the nominal value of the preference share (£0.000001 per share).

(I) Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares are shown in equity as a deduction, net of income taxes, from the proceeds. Where the Company purchases the Company's own equity instruments, for example as the result of a share buy-back or a share-based payment plan, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the owners as treasury shares until the shares are cancelled or reissued.

Where ordinary shares are subsequently reissued, any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity.

(J) Income taxes

Current income taxes

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

or substantively enacted at the reporting date in the countries where the Company operates and generates taxable income. Current income taxes relating to items recognized directly in equity are recognized in equity and not in the statement of total comprehensive income. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred income taxes

Deferred income taxes are provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred income tax liabilities are recognized for all taxable temporary differences, except:

- When the deferred income tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred income tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized, except:

- When the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or a liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred income tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Unrecognized deferred income tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred income tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred income taxes relating to items recognized outside profit or loss is recognized outside profit or loss. Deferred income tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

Tax benefits acquired as part of a business combination, but not satisfying the criteria for separate recognition at that date, are recognized subsequently if new information about facts and circumstances change. The

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

adjustment is either treated as a reduction in goodwill (as long as it does not exceed goodwill) if it was incurred during the measurement period or recognized in profit or loss.

The Company offsets deferred income tax assets and deferred income tax liabilities if and only if it has a legally enforceable right to set off current income tax assets and current income tax liabilities and the deferred income tax assets and deferred income tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities, which intend either to settle current income tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred income tax liabilities or assets are expected to be settled or recovered.

4. Cash and cash equivalents

Cash and cash equivalents consist of the following:

	As at 31 December			
	2022		2021	
Demand deposits held with banks	\$	0.2	\$	0.2
Total cash and cash equivalents	\$	0.2	\$	0.2

5. Interest receivable – related party

Interest receivable – related party consists of \$150.8 million in loan interest receivable from PE Titan III, a related party.

Changes to the Company's interest receivable – related party in the years ended 31 December 2022 and 2021 are as follows:

Ending balance as at 31 December 2020	\$	60.8
Loan interest receivable recorded in the period	\$	43.3
Ending balance as at 31 December 2021	\$	104.1
Loan interest receivable recorded in the period	\$	46.7
Ending balance as at 31 December 2022	\$	150.8

6. Loans receivable – related party

Loans receivable – related party consists of \$486.1 million in loans receivable from PE Titan III, a related party.

Changes to the Company's loans receivable – related party in the years ended 31 December 2022 and 2021 are as follows:

Interest-bearing credit facilities – Non-current assets		
Ending balance as at 31 December 2020	\$	486.1
Loan repayments	\$	-
Ending balance as at 31 December 2021	\$	486.1
Loan repayments	\$	-
Ending balance as at 31 December 2022	\$	486.1

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

7. Investment in subsidiary

On May 19, 2019, the Company obtained one ordinary share of PE Titan III in exchange for \$272.3 million of non-interest-bearing loan, which has been recorded in the Company's statement of financial position as investment in subsidiary. There were no changes in this balance during the years ended 31 December 2022 and 2021.

8. Income taxes

The major components of income tax expense for the years ended 31 December 2022 and 2021 are as follows:

	For the Years Ended 31 December	
	2022	2021
Current income taxes	\$ -	\$ -
Deferred income taxes	\$ 8.9	\$ 8.2
Income tax expense recognized in profit or loss	\$ 8.9	\$ 8.2

The Company has taken the tax benefits from its subsidiary resulting in no tax liability at the individual account. The provision for income taxes that would be obtained by applying the United Kingdom statutory income tax rate is as follows:

	For the Years Ended 31 December	
	2022	2021
Net income before income taxes	\$ 46.7	\$ 43.3
United Kingdom statutory tax rate	19.0%	19.0%
Expected income tax expense at statutory rate	\$ 8.9	\$ 8.2
Adjustments:		
Losses claimed from subsidiary for group relief	\$ -	\$ -
Effective income tax expense	\$ 8.9	\$ 8.2

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

9. Fair value measurements

The carrying amounts and the estimated fair values of the Company's financial assets that qualify as financial instruments are as follows:

	As at 31 December			
	2022		2021	
	Carrying amount	Fair value	Carrying amount	Fair value
Financial assets:				
Loans receivable – related party	\$ 486.1	\$ 486.1	\$ 486.1	\$ 486.1
Total financial assets	\$ 486.1	\$ 486.1	\$ 486.1	\$ 486.1

The fair value represents the price that would be received to sell an asset or transfer a liability in an orderly transaction between market participants at the measurement date.

The carrying amount for cash and cash equivalents and interest receivable – related party, approximates fair value for the years presented due to their short-term maturity and a demand feature.

10. Ordinary and preference shares

As at both 31 December 2022 and 2021, the Company had 546,297,206.3 million ordinary shares issued and outstanding. As at both 31 December 2022 and 2021, the Company had one preference share issued and outstanding.

	Preference shares		Ordinary shares		Share premium
	Shares	Amount	Shares	Amount	
Balance as at 31 December 2022 and 2021	-	-	546,297,206.3	\$ 546.3	\$ 179.9

11. Interest income

The Company recorded \$46.7 million and \$43.3 million in interest income from related party loans for the years ended 31 December 2022 and 2021, respectively.

12. Risk management

The Company's principal financial assets include investment in subsidiary, interest receivable – related party, loans receivable – related party, and cash and cash equivalents that derive directly from its operations.

The Company is exposed to credit risk, liquidity risk, and interest rate risk. The Company's senior management oversees the management of these risks and appropriateness of financial risk governance framework for the Company. The Company's senior management assures that the Company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives. It is the Company's policy that no trading in derivatives for speculative purposes may be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarized below.

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to perform its obligations causing a loss for the other. The Company's financial assets exposed to credit risk consist primarily of cash and cash equivalents, interest receivable – related party, and loans receivable – related party.

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

Liquidity risk

Liquidity risk is the risk that the Company will have difficulty meeting its financial obligations as they come due. The Company manages liquidity risk by preparing and monitoring forecasts to ensure that the Company has sufficient funds to meet its financial obligations and fund new business opportunities or other unanticipated requirements as they arise. The Company manages this risk by monitoring PE Titan III's performance.

Interest rate risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate with changes in market interest rates. The Company is primarily exposed to interest rate risk through its loans receivable from PE Titan III. The interest rates related to the loans receivable from PE Titan III are fixed.

13. Indemnifications

In the ordinary course of business, the Company has entered into agreements that include indemnifications in favour of third parties related mainly to lending agreements. Such agreements do not specifically quantify the Company's liability and, therefore, it is not possible to estimate the potential liability under these indemnities. Historically, the Company has not made any significant payments under indemnifications provided in the ordinary course of business.

14. Related party disclosures

The Company is majority owned by PE Titan.

The Company's wholly owned and indirect wholly owned subsidiaries, are as follows:

Legal name	Country of incorporation	Registered address	Class of shares held	Ownership %	Ownership
PE Titan Holding III Limited	United Kingdom	100 New Bridge Street, London, EC4V 6JA	Ordinary shares	100%	PE Titan Holding II
Husky Technologies Limited (f/k/a Titan I Holding Limited)	Canada	Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8	Class A ordinary shares Class B and Series 2 Class B ordinary shares	96.4% 3.6%	PE Titan Holding III Management
Titan II Holding Limited	United Kingdom	100 New Bridge Street, London, EC4V 6JA	Class A ordinary shares Class A preference Shares	100%	Husky Technologies Limited
Husky III Holding Limited (f/k/a Titan III Holding Limited)	Canada	Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8	Common shares	100%	Titan II Holding Limited
Husky IV Holding Limited (f/k/a Titan IV Holding Limited)	Canada	Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8	Class A preference shares Class A ordinary shares	68.5% 31.5%	Husky III Holding Limited Husky VI Finance Holding Limited
Husky VI Finance Holding Limited	Canada	Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8	Common shares	100%	Husky III Holding Limited
Husky Injection Molding Systems Ltd.	Canada	Suite 1700, Par Place, 666 Burrard Street, Vancouver, B.C. V6C 2X8	Common shares	100%	Husky IV Holding Limited
Husky Injection Molding Systems Argentina S.A.	Argentina	c/o Zapiola 2375, Piso 6, Oficina "A", Ciudad Autonoma de Buenos Aires	Common shares	99.1% 0.9%	Husky Injection Molding Systems Ltd. Husky Injection Molding Systems

Notes to the Annual Financial Statements

Year Ended 31 December 2022

In millions of U.S. dollars and millions of shares

Husky Injection Molding Systems ANZ Pty Limited	Australia	Suite A40B, Level 5 24 Lexington Drive Norwest Business Park Bella Vista NSW 2153 Australia	Common shares	100%	Colombia Ltd. Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems Austria (GmbH)	Austria	Brunnerstrasse 38 A-3830 Waidhofen an der Thaya Austria	Capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems (Belgium) S.A.	Belgium	c/o 6700 Arlon, Avenue General Patton, 52	Common shares	100%	Husky Injection Molding Systems S.A.
Husky do Brazil Sistemas de Injecao Ltda.	Brazil	Rod. Dom Gabriel Paulino Bueno Cuoto, KM 66.5 13216 – 990 Jundai SP, Brazil	Common Stock	99.999997%	Husky Injection Molding Systems Ltd.
		P.O. Box 2503		0.000003%	Husky Injection Molding Systems Colombia Ltd.
Husky Injection Molding Systems Private Limited	India	P47, Eight Avenue Domestic Tariff Area, Natham Sub Post Office, Mahindra World City Chengalpattu Tamil Nadu, 603 002, India	Equity shares	99.999998%	Husky Injection Molding Systems Singapore Pte. Ltd. Husky Injection Molding Systems Ltd.
				0.000002%	
Husky Injection Molding Systems (Chile) S.A.	Chile	c/o Av. Nueva Tajamar 481 Torro norte, piso 21 Las Condes, Santiago Chile	Common shares	99.99%	Husky Injection Molding Systems Ltd. Husky Injection Molding Systems Colombia Ltd.
				0.01%	
Husky Injection Molding Systems Colombia Ltd.	Colombia	c/o Ceron Alvarez & Associates Ltda. Cra 13 No 93-40 Of. 303 Bogota, Columbia	Common shares	100%	Husky Injection Molding Systems Ltd.

Notes to the Annual Financial Statements

Year Ended 31 December 2022

In millions of U.S. dollars and millions of shares

Husky Injection Molding Systems (Nordic) A/S	Denmark	Orestads Boulevard 73 DK-2300 Copenhagen Denmark	Common shares	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems S.A.R.L	France	c/o 31 cours de Verdun 01100 Oyonnax France	Common shares	100%	Husky Injection Molding Systems S.A.
Husky Spritzgiess – System GmbH	Germany	c/o Adelungstrasse 23 64283 Darmstadt Germany	Capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems (Israel) Ltd.	Israel	P.O.B. 3593 Haeshel St. 7, Zone 2 Caesarea Industrial Park, 38900 Israel	Capital	100%	Husky Injection Molding Systems S.A.
Husky Italia S.r.l.	Italy	c/o Viale Monte Nero n. 84	Capital	100%	Husky Injection Molding Systems S.A.
Husky Corporation	Japan	20123 Milano Italy 5-10-1 Minami Machida, Machida-SHI Tokyo 194-0005	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems Korea Inc.	Korea	Rm 1110, Ace Twin Tower 1 212-1, Guro-3dong Guro-gu Seoul, South Korea 152- 848	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky KTW GesmbH	Austria	Brunnerstrasse 38 A-3830 Waidhofen an der Thaya Austria	Capital	95% 5%	Husky Injection Molding Systems Austria GmbH Husky Injection Molding Systems S.A. Husky-KTW GesmbH
Husky KTW s.r.o	Czech Republic	Dolni Pena 200	Capital	100%	

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S dollars and millions of shares

Husky Injection Molding Systems Malaysia SDN. BHD.	Malaysia	377 01 Jindrichuv Hradec Czech Republic c/o Suite 13.03, 13 th floor Menara Tan & Tan 207 Jalan Tim Razak 50400 Kuala Lumpur	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems Mexico, S.A. de C.V.	Mexico	Avenida Prolongacion Paseo de la Reforma #1236 Piso 1 Colonia Santa Fe Cuajimalpa CDMX CP 05348	Fixed Capital Variable Capital	99.994% 0.005%	Husky Injection Molding Systems Ltd. Husky Injection Molding Systems Colombia Ltd.
Husky Injection Molding Systems (Philippines), Inc.	Philippines	16th floor, 1601 Robinsons Summit Center 6783 Ayala Avenue Makati City, Philippines	Common shares	99.9936% 0.0064%	Husky Injection Molding Systems Ltd. Directors
Husky CIS Limited Liability Company	Russia	Kuskovskaya ul, 20A Block A, 5 th floor of. 511 111141 Moscow, Russia	Charter capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems S.A.	Luxembourg	Zone d'activité économique Wolser H 170 , L-3451 Dudelange Luxembourg	Shares	100%	Husky Injection Molding Systems Luxembourg Holdings S.a.r.l.
Husky Injection Molding Systems Luxembourg Holdings S.a.r.l.	Luxembourg	Zone d'activité économique Wolser H 170 L-3451 Dudelange Luxembourg	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems IP Holdings S.a.r.l.	Luxembourg	Zone d'activité économique Wolser H 170	Fixed Capital	100%	Husky Injection Molding Systems S.A.

Notes to the Annual Financial Statements

Year Ended 31 December 2022

In millions of U.S. dollars and millions of shares

Husky Injection Molding Systems Luxembourg IP Development S.a.r.l.	Luxembourg	L-3451 Dudelange Luxembourg Zone d'activité économique Wolser H 170 L-3451 Dudelange Luxembourg	Capital	100%	Husky Injection Molding Systems IP Holdings S.a.r.l.
Husky Injection Molding Systems (Shanghai) Ltd.	China Shanghai	Shanghai Technical Center 101 Ba Sheng Road China (Shanghai) Pilot Free Trade Zone P.R. China 200131	Registered capital	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems (Shenzhen) Ltd.	China Shenzhen	Room 2507, Huiju Innovation Park, Liuxian Avenue 2, Xin'an Community, Bao'an District, Shenzhen, China	Registered capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems Singapore Pte. Ltd.	Singapore	C/o 80, Changi Road, #03-22, CentroPod, Singapore 419715	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems (South Africa) Proprietary Limited	South Africa	22 Wellington Road Parktown, 2193 South Africa	Common shares	100%	Husky Injection Molding Systems Ltd.
Husky Injection Molding Systems Iberia S.L.U.	Spain	c/o Ronda General Mitre 28-30 08017 Barcelona, Spain	Capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems (Thailand) Ltd.	Thailand	252/100 (B), 20th Floor, Tower 2, Muang Thai-Phatra Complex Building, Ratchadaphisek Road, Huaykwang Sub-district,	Common shares	99.99%	Husky Injection Molding Systems Singapore Pte. Ltd.
				0.001%	Nominee shareholders

Notes to the Annual Financial Statements
Year Ended 31 December 2022
In millions of U.S. dollars and millions of shares

Husky Injection Molding Systems (UK) Limited	United Kingdom	Huaykwang District, Bangkok 10310 100 New Bridge Street, London EC4V 6JA	Ordinary shares	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems, Inc.	United States	288 North Road Milton VT 05468	Capital	100%	Husky Injection Molding Systems S.A.
Husky Injection Molding Systems Vietnam Co. Limited	Vietnam	1DD Building 111 Ly Chinh Thang, Ward 7 District 3 10 th Floor Ho Chi Minh City Vietnam	Capital	100%	Husky Injection Molding Systems Singapore Pte. Ltd.
Schottli AG	Switzerland	Industrie Grossholz 8253 Diessenhofen Switzerland	Registered shares	100%	Husky Injection Molding Systems S.A.
Magor Mold, LLC	United States	818 West Seventh Street, Suite 930, Los Angeles, CA 90017	Limited liability interest	100%	Husky Injection Molding Systems, Inc.

Transactions with other related parties

All transactions are with related parties.

There was no key management compensation for the years ended 31 December 2022 and 2021.

15.Ultimate controlling company and parent company of larger group

The Company's immediate parent undertaking is PE Titan, a company registered in England and Wales.

The ultimate controlling party is Platinum Equity Capital Partners International IV (Cayman), L.P.

The smallest and largest group in which the results of the Company are consolidated is that headed by PE Titan. No other group financial statements include the results of the Company. The consolidated financial statements of the group are available to the public and may be obtained from 100 New Bridge Street, London EC4V 6JA.

16.Directors' remuneration

The Company, PE Titan III and PE Titan have the same three directors, and one of those directors was paid approximately ten thousand two hundred dollars and nine thousand seven hundred dollars for the years ended 31 December 2022 and 2021 respectively.

Three of the Husky Injection Molding Systems Limited's ("Husky's") direct and indirect subsidiaries have the same director. This director was paid five thousand dollars for the years ended 31 December 2022 and 2021.

The directors for Husky's remaining subsidiaries are Husky paid employees with the exception of nominee directors at *Husky Injection Molding Systems Argentina S.A.*, and *Husky Injection Molding Systems (Philippines), Inc.* The nominee directors are paid retainer fees that are not material.

There was no other director remuneration incurred or paid for the years ended 31 December 2022 and 2021.

17.Subsequent events

There were no subsequent events, which have been evaluated through the date the financial statements were issued.